Unraveling the biology of ME/CFS and long COVID

Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are highly complex conditions with many different biological causes and risk factors.

Until recently, not a single replicable genetic finding had been reported for either condition in over 30 years of global research.

PrecisionLife has now identified the very first genetic mechanisms underlying both ME/CFS and long COVID with biomarkers that stratify the patients with that underlying biology.

With this new level of understanding, we're leading international efforts to bring a precision medicine approach to the diagnosis, treatment, and prevention of ME/CFS and long COVID, conducting groundbreaking research to:

1. Validate rapid non-invasive tests to detect risks and identify the causes of ME/CFS and long COVID in individuals
2. Identify actively protective biology to prevent people from getting ME/CFS and long COVID and aid recovery
3. Find and validate drug candidates that can be repurposed to treat ME/CFS, long COVID and related conditions

Our progress to date

Read the report of our progress made in understanding ME/CFS and long COVID and finding new diagnostic and therapeutic options.

Published research
Reproducibility of Genetic Risk Factors Identified for Long COVID using Combinatorial Analysis Across US and UK Patient Cohorts with Diverse Ancestries  Journal of Translational Medicine	Identifying Genetic Risk Factors for ME/CFS and Long COVID  Poster detailing our discovery of the first genetic associations, novel targets, actively protective biology, and diagnostics.
Genetic Risk Factors for ME/CFS Identified using Combinatorial Analysis Journal of Translational Medicine	Genetic Risk Factors for Severe and Fatigue Dominant Long COVID and Commonalities with ME/CFS Identified by Combinatorial Analysis Journal of Translational Medicine

Video presentations
Genomics and Genetic Susceptibilities of ME Presented at the NIH ME/CFS Research Roadmap Webinar 2024	Precision Medicine for Long COVID and ME/CFS Presented at the Unite to Fight ME Conference 2024

 

The Causal Biology of ME Presented at the Invest in ME Research Congress 2024

 

 

News announcements
PrecisionLife and Metrodora Foundation announce confirmation of key genetic findings for long COVID across diverse populations	PrecisionLife and Metrodora Institute share first insights with ME/CFS, Long COVID participants in MetX study
Precision Medicine Clinical Trials Lunched for ME/CFS and Long Covid to Accelerate Diagnosis and Treatment	PrecisionLife Project Awarded Innovate UK Grant to Improve Diagnosis and Treatment of ME/CFS and Long Covid

 

 

Blogs
How new research confirmed long COVID genetic associations for diagnostics and treatments	New Study Links 14 Genes to ME/CFS By Simon McGrath for the ME/CFS Research Review

Partners

Datasets

About PrecisionLife

PrecisionLife is a clinical-stage precision medicine company creating better diagnostic tools and more personalized treatment options to predict, treat, and prevent complex chronic diseases, which affect over 5 billion patient lives and account for over 80% of healthcare spending.

Our unique AI-led combinatorial analytics platform is unparalleled in its ability to identify causal disease biology – revealing the underlying drivers of many diseases for the first time, linking individuals to the treatments that will benefit them most, and accurately predicting lifetime risk of disease.

PrecisionLife’s precision medicine insights and diagnostic tools hold the key to reducing the global burden of chronic diseases, improving the rate of successful drug development, and increasing healthspan for billions of people.

Contact us via the form below to find out more about partnering with PrecisionLife.